Posaconazole is an azole antifungal indicated as follows, among other approved uses. It is available as delayed-release tablets, injection and tablets for oral and intravenous use. MedsAcross supplies Posaconazole for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Posaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 2 years of age and older who weigh greater than 40 kg.
Source: US FDA prescribing information
Posaconazole is an azole antifungal agent.
Source: US FDA prescribing information
Posaconazole formulations are supplied in different dose strengths of posaconazole, are approved for different indications, age groups, and weights, have different dosages and duration of therapy, and have different preparation and administration instructions. Posaconazole oral suspension is not substitutable with Posaconazole delayed-release tablets or Noxafil PowderMix for delayed-release oral suspension due to the differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for each of the formulations. Administer Posaconazole delayed-release tablets with or without food. Administer Posaconazole oral suspension with a full meal. See the full prescribing information for important administration and preparation instructions for Posaconazole (delayed-release tablets and Posaconazole oral suspension.
Source: US FDA prescribing information
Known hypersensitivity to posaconazole or other azole antifungal agents. Coadministration of posaconazole with the following drugs is contraindicated: posaconazole increases concentrations and toxicities of: Sirolimus. CYP3A4 substrates (pimozide, quinidine): can result in QTc interval prolongation and cases of torsades de pointes (TdP). HMG-CoA Reductase Inhibitors Primarily Metabolized through CYP3A4. Ergot alkaloids. Venetoclax: In patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) at initiation and during the ramp-up phase
Source: US FDA prescribing information
Calcineurin-Inhibitor Toxicity: Posaconazole increases concentrations of cyclosporine or tacrolimus, reduce dose of cyclosporine and tacrolimus and monitor concentrations frequently. Arrhythmias and QTc Prolongation: Posaconazole has been shown to prolong the QTc interval and cause cases of TdP. Administer with caution to patients with potentially proarrhythmic conditions. Do not administer with drugs known to prolong QTc interval and metabolized through CYP3A4. Electrolyte Disturbances: Monitor and correct, especially those involving potassium (K + ), magnesium (Mg ++ ), and calcium (Ca ++ ), before and during posaconazole therapy. Pseudoaldosteronism: Manifested by the onset or worsening of hypertension, and abnormal laboratory findings. Monitor blood pressure and potassium levels, and manage as necessary. Hepatic Toxicity: Elevations in liver tests may occur.
Source: US FDA prescribing information
The following serious and otherwise important adverse reactions are discussed in detail in another section of the labeling: Arrhythmias and QT Prolongation Electrolyte Disturbances Pseudoaldosteronism Hepatic Toxicity Common adverse reactions in studies with posaconazole are diarrhea, nausea, fever, vomiting, headache, coughing, and hypokalemia.
Source: US FDA prescribing information
Table 12 and Table 13 include drugs with clinically important drug interactions when administered concomitantly with posaconazole and instructions for preventing or managing them. Table 14 includes important drug interactions specific to the absorption of posaconazole administered as Posaconazole oral suspension. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy. The following information was derived from data with Noxafil oral suspension or another posaconazole tablet formulation unless otherwise noted.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Posaconazole Oral Suspension Store at 25°C (77°F), excursions permitted to 15 to 30°C (59 to 86°F). DO NOT FREEZE.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Posaconazole, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Posaconazole 100 mg delayed-release tabletOralGeneric name | — | US FDA | Available on request |
| Posaconazole 300.6 mg/16.7 mL injectionIntravenous Cold chainGeneric name | — | US FDA | Available on request |
| Posaconazole 100 mg tabletOralGeneric name | — | US FDA | Available on request |
| Posaconazole 40 mg/mL oral suspensionOralGeneric name | — | US FDA | Available on request |
| Noxafil 100 mg tabletOral Cold chain | Merck Sharp & Dohme | US FDA | Available on request |
| Noxafil 300 mg powder for oral suspensionOral Cold chain | Merck Sharp & Dohme | US FDA | Available on request |
| Noxafil 300.6 mg/16.7 mL injectionIntravenous Cold chain | Merck Sharp & Dohme | US FDA | Available on request |
| Noxafil 40 mg/mL oral suspensionOral Cold chain | Merck Sharp & Dohme | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Posaconazole in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Posaconazole and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Posaconazole, including Noxafil.
Yes. The US FDA first approved Posaconazole on 15 September 2006, according to Drugs@FDA.
Yes. Posaconazole has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Posaconazole must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Posaconazole is classified under ATC code J02AC04 (Posaconazole).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.